サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1511837

米国の糖尿病性足潰瘍治療の市場規模、シェア、動向分析レポート：治療別、潰瘍タイプ別、最終用途別、セグメント別予測、2024年-2030年

U.S. Diabetic Foot Ulcer Treatment Market Size, Share & Trends Analysis Report By Treatment (Therapy Device, Wound Care Dressing), By Ulcer Type (Ulcer, Neuro-ischemic Ulcer), By End-use, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 180 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
米国の糖尿病性足潰瘍治療の市場規模、シェア、動向分析レポート：治療別、潰瘍タイプ別、最終用途別、セグメント別予測、2024年-2030年
出版日: 2024年06月11日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の糖尿病性足潰瘍治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の糖尿病性足潰瘍治療市場規模は、2024年から2030年にかけてCAGR 5.25%で拡大し、2030年には24億7,000万米ドルに達すると予測されています。

市場開拓の主な要因としては、全国的な糖尿病発症の増加、高齢化、治療技術の進歩、研究開発努力の高まり、ライフスタイルパターンの変化などが挙げられます。例えば、人口問題研究所の予測によると、65歳以上のアメリカ人人口は2022年の5,800万人から2050年には8,200万人へと47%増加すると予想されています。

糖尿病性足潰瘍は一般的な合併症であるため、米国における糖尿病の流行は市場拡大に大きな役割を果たしています。例えば、国際糖尿病連合によると、2021年の米国の20～79歳の糖尿病患者は約3,221万人で、2045年にはさらに3,628万人に増加すると予測されています。さらに、医療技術や治療方法の進歩も市場の成長に寄与しています。先進的な創傷ケア製品、生体工学的組織、再生医療技術などの革新は、糖尿病性足潰瘍管理により効果的かつ効率的なソリューションを提供しています。

さらに、糖尿病性足潰瘍の早期発見と適切な治療の重要性に対するヘルスケアプロバイダーと患者の意識の高まりが、市場の成長を促進しています。ヘルスケア専門家も患者も、糖尿病性足潰瘍を早期に発見するためには入念なフットケアと定期的な検診が必要であることを理解しています。このような意識の高まりは、糖尿病合併症の管理に対する積極的なアプローチを促し、患者の予後改善と重症潰瘍の減少につながっています。さらに、糖尿病性足潰瘍を管理するための治療オプションや技術を進歩させるためには、継続的な研究開発の努力が不可欠です。このような継続的な努力の結果、新しい治療法、診断ツール、予防法などの革新的なソリューションが生まれ、ヘルスケア提供者が利用できる選択肢が広がっています。

大手市場参入企業の存在や、製品承認、製品上市、提携、M&A、事業拡大など、市場競争力を維持するために各企業が行っているさまざまな取り組みが、市場全体の成長に寄与すると予想されます。例えば、2024年4月、Molnlycke Health Care社は、創傷洗浄・保湿製品のGranudacynの製造で知られるオーストリアのP.G.F. Industry Solutions GmbH社を買収する計画を発表しました。

米国の糖尿病性足潰瘍治療市場レポート・ハイライト

  • 治療別では、生物学的製剤分野が2023年に30％以上の売上シェアを獲得して市場を独占。
  • 治療機器分野は予測期間中に最も速いCAGRで成長すると予測されます。
  • 潰瘍タイプ別では、神経虚血性潰瘍分野が2023年に最大の市場シェアを占めました。
  • 虚血性潰瘍セグメントは2024年から2030年にかけて最も速い速度で成長すると予測されています。
  • 最終用途別では、病院と診療所が2023年の市場をリードしました。
  • 北米が2023年の市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の糖尿病性足潰瘍治療市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 米国の糖尿病性足潰瘍治療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国の糖尿病性足潰瘍治療市場：治療の推定・動向分析

  • セグメントダッシュボード
  • 米国の糖尿病性足潰瘍治療市場：治療の変動分析
  • 米国の糖尿病性足潰瘍治療市場規模と動向分析、治療別、2018～2030年
  • 創傷ケア用ドレッシング
  • 生物学的製剤
  • 治療機器
  • 抗生物質
  • その他

第5章 米国の糖尿病性足潰瘍治療市場：潰瘍タイプの推定・動向分析

  • セグメントダッシュボード
  • 米国の糖尿病性足潰瘍治療市場：潰瘍タイプの変動分析
  • 米国の糖尿病性足潰瘍治療市場規模と動向分析、潰瘍タイプ別、2018～2030年
  • 市場規模と予測および動向分析、2018年から2030年
  • 神経障害性潰瘍
  • 虚血性潰瘍
  • 神経虚血性潰瘍

第6章 米国の糖尿病性足潰瘍治療市場：最終用途の推定・動向分析

  • セグメントダッシュボード
  • 米国の糖尿病性足潰瘍治療市場：最終用途の変動分析
  • 米国の糖尿病性足潰瘍治療市場規模と動向分析、最終用途別、2018～2030年
  • 病院
  • 外来手術センター
  • 在宅ケア

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • 主要企業の市場シェア分析、2023年
  • 企業のポジション分析
  • 企業分類（新興企業、イノベーター、リーダー）
  • 企業プロファイル
    • ConvaTec, Group Plc
    • 3M Health Care
    • Coloplast Corp.
    • Smith &Nephew Plc
    • B Braun Melsungen AG
    • Medline Industries, LP.
    • Molnlycke Health Care AB
    • Medtronic Plc
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. U.S. diabetic foot ulcer treatment market by treatment, 2018 - 2030 (USD Million)
  • Table 4 U.S. U.S. diabetic foot ulcer treatment market by ulcer type, 2018 - 2030 (USD Million)
  • Table 5 U.S. U.S. diabetic foot ulcer treatment market by end use, 2018 - 2030 (USD Million)
  • Table 6 Participant's overview
  • Table 7 Financial performance
  • Table 8 Key companies undergoing expansions
  • Table 9 Key companies undergoing acquisitions
  • Table 10 Key companies undergoing collaborations
  • Table 11 Key companies launching new products/services
  • Table 12 Key companies undergoing partnerships
  • Table 13 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2023 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Porter's analysis
  • Fig. 13 SWOT analysis
  • Fig. 14 US diabetic foot ulcer treatment market: Treatment outlook and key takeaways
  • Fig. 15 US diabetic foot ulcer treatment market: Treatment movement analysis
  • Fig. 16 Wound care dressings market, 2018 - 2030 (USD Million)
  • Fig. 17 Alginate dressings market, 2018 - 2030 (USD Million)
  • Fig. 18 Hydrofiber dressings market, 2018 - 2030 (USD Million)
  • Fig. 19 Foam dressings market, 2018 - 2030 (USD Million)
  • Fig. 20 Film dressing market, 2018 - 2030 (USD Million)
  • Fig. 21 Hydrocolloid dressings market, 2018 - 2030 (USD Million)
  • Fig. 22 Surgical dressings market, 2018 - 2030 (USD Million)
  • Fig. 23 Hydrogel dressings market, 2018 - 2030 (USD Million)
  • Fig. 24 Biologics market, 2018 - 2030 (USD Million)
  • Fig. 25 Growth factors market, 2018 - 2030 (USD Million)
  • Fig. 26 Skin grafts market, 2018 - 2030 (USD Million)
  • Fig. 27 Therapy devices market, 2018 - 2030 (USD Million)
  • Fig. 28 Negative pressure Wound Therapy market, 2018 - 2030 (USD Million)
  • Fig. 29 Ultrasound therapy market, 2018 - 2030 (USD Million)
  • Fig. 30 Antibiotic medications market, 2018 - 2030 (USD Million)
  • Fig. 31 Others market, 2018 - 2030 (USD Million)
  • Fig. 32 US diabetic foot ulcer treatment market: Ulcer type outlook and key takeaways
  • Fig. 33 US diabetic foot ulcer treatment market: Ulcer type movement analysis
  • Fig. 34 Neuropathic ulcers market, 2018 - 2030 (USD Million)
  • Fig. 35 Ischemic ulcers market, 2018 - 2030 (USD Million)
  • Fig. 36 Neuro-ischemic ulcers market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. diabetic foot ulcer treatment market: End Use outlook and key takeaways
  • Fig. 38 U.S. diabetic foot ulcer treatment market: End Use movement analysis
  • Fig. 39 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 40 Ambulatory surgery centre market, 2018 - 2030 (USD Million)
  • Fig. 41 Homecare market, 2018 - 2030 (USD Million)
  • Fig. 42 Heat map analysis
  • Fig. 43 Market participant categorization
  • Fig. 44 U.S. diabetic foot ulcer treatment market share analysis, 2023
  • Fig. 45 Strategy framework
目次
Product Code: GVR-4-68040-302-9

U.S. Diabetic Foot Ulcer Treatment Market Growth & Trends:

The U.S. diabetic foot ulcer treatment market size is anticipated to reach USD 2.47 billion by 2030, expanding at a CAGR of 5.25% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major factors contributing to market growth include the increasing occurrence of diabetes nationwide, an aging population, advancements in treatment technology, rising research and development efforts, and shifts in lifestyle patterns. For instance, according to the Population Reference Bureau's projections, the population of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by the year 2050, reflecting a 47% increase.

The prevalence of diabetes in the U.S. plays a significant role in market expansion, as diabetic foot ulcers are a common complication of the disease. For instance, according to the International Diabetes Federation, in 2021 there were about 32.21 million diabetes patients aged 20-79 years in the U.S. which are further expected to increase to 36.28 million by 2045. Furthermore, the advancements in medical technology and treatment modalities contribute to the growth of the market. Innovations such as advanced wound care products, bioengineered tissues, and regenerative medicine techniques offer more effective and efficient solutions for diabetic foot ulcer management.

Furthermore, the increasing awareness among healthcare providers and patients of the importance of early detection and proper treatment of diabetic foot ulcers is driving the market growth. Both healthcare professionals and patients understand the necessity of careful foot care and regular screenings to catch diabetic foot ulcers early. This heightened awareness encourages a proactive approach to managing complications of diabetes, leading to better outcomes for patients and fewer severe ulcers. Additionally, ongoing research and development efforts are essential in advancing treatment options and technologies for managing diabetic foot ulcers. These continued efforts result in innovative solutions, such as new therapies, diagnostic tools, and preventive measures, which expand the options available to healthcare providers.

Presence of major market participants and various initiatives undertaken by them to stay competitive in the market such as product approval, product launch, partnership, merger and acquisition, expansion, etc. are expected to contribute to the overall market growth. For instance, in April 2024, Molnlycke Health Care has announced its plans to acquire P.G.F. Industry Solutions GmbH, an Austrian company known for producing Granudacyn, a line of wound cleansing and moisturizing products.

U.S. Diabetic Foot Ulcer Treatment Market Report Highlights:

  • Based on treatment, the biologics segment dominated the market by capturing a revenue share of more than 30% in 2023
  • The therapy devices segment is anticipated to grow at the fastest CAGR during the forecast period
  • Based on ulcer type, the neuro-ischemic ulcers segment held the largest market share in 2023
  • The Ischemic ulcers segment is expected to grow at a fastest rate from 2024 to 2030
  • Based on end-use, hospitals and clinics led the market in 2023
  • North America dominated the market in 2023

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Ulcer Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. Ulcer type outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Diabetic Foot Ulcer Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing prevalence of diabetes
      • 3.2.1.2. Aging population
      • 3.2.1.3. Advancements in treatment technology
      • 3.2.1.4. Lifestyle changes
      • 3.2.1.5. Growing R&D activities
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
  • 3.3. U.S. Diabetic Foot Ulcer Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Diabetic Foot Ulcer Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global U.S. Diabetic Foot Ulcer Treatment Market Movement Analysis
  • 4.3. Global U.S. Diabetic Foot Ulcer Treatment Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Wound Care Dressings
    • 4.4.1. Wound care dressings market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.4.1.1. Alginate dressings
      • 4.4.1.1.1. Alginate dressing market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.4.1.2. Hydrofiber dressings
      • 4.4.1.2.1. Hydrofiber dressings market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.4.1.3. Foam dressings
      • 4.4.1.3.1. Foam dressings market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.4.1.4. Film dressing
      • 4.4.1.4.1. Film dressings market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.4.1.5. Hydrocolloid dressings
      • 4.4.1.5.1. Hydrocolloid dressings market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.4.1.6. Surgical Dressings
      • 4.4.1.6.1. Surgical dressings market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.4.1.7. Hydrogel dressings
      • 4.4.1.7.1. Hydrogel dressings market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Biologics
    • 4.5.1. Biologics market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.5.1.1. Growth factors
      • 4.5.1.1.1. Growth factors market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.5.1.2. Skin grafts
      • 4.5.1.2.1. Skin grafts market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Therapy devices
    • 4.6.1. Therapy devices market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.6.1.1. Negative pressure wound therapy
      • 4.6.1.1.1. Negative pressure wound therapy market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.6.1.2. Ultrasound therapy
      • 4.6.1.2.1. Ultrasound therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Antibiotic medicine
    • 4.7.1. Antibiotic medicine market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Diabetic Foot Ulcer Treatment Market: Ulcer Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global U.S. Diabetic Foot Ulcer Treatment Ulcer Type Market Movement Analysis
  • 5.3. Global U.S. Diabetic Foot Ulcer Treatment Market Size & Trend Analysis, by Ulcer Type, 2018 to 2030 (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.5. Neuropathic Ulcers
    • 5.5.1. Neuropathic ulcers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Ischemic Ulcers
    • 5.6.1. Ischemic ulcers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Neuro-ischemic Ulcers
    • 5.7.1. Neuro-ischemic ulcers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Diabetic Foot Ulcer Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global U.S. Diabetic Foot Ulcer Treatment End Use Market Movement Analysis
  • 6.3. Global U.S. Diabetic Foot Ulcer Treatment Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Surgery Center
    • 6.5.1. Ambulatory surgery center market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Homecare
    • 6.6.1. Homecare market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share analysis, 2023
  • 7.4. Company Position Analysis
  • 7.5. Company Categorization (Emerging Players, Innovators and Leaders
  • 7.6. Company Profiles
    • 7.6.1. ConvaTec, Group Plc
      • 7.6.1.1. Company overview
      • 7.6.1.2. Financial performance
      • 7.6.1.3. Product benchmarking
      • 7.6.1.4. Strategic initiatives
    • 7.6.2. 3M Health Care
      • 7.6.2.1. Company overview
      • 7.6.2.2. Financial performance
      • 7.6.2.3. Product benchmarking
      • 7.6.2.4. Strategic initiatives
    • 7.6.3. Coloplast Corp.
      • 7.6.3.1. Company overview
      • 7.6.3.2. Financial performance
      • 7.6.3.3. Product benchmarking
      • 7.6.3.4. Strategic initiatives
    • 7.6.4. Smith & Nephew Plc
      • 7.6.4.1. Company overview
      • 7.6.4.2. Financial performance
      • 7.6.4.3. Product benchmarking
      • 7.6.4.4. Strategic initiatives
    • 7.6.5. B Braun Melsungen AG
      • 7.6.5.1. Company overview
      • 7.6.5.2. Financial performance
      • 7.6.5.3. Product benchmarking
      • 7.6.5.4. Strategic initiatives
    • 7.6.6. Medline Industries, LP.
      • 7.6.6.1. Company overview
      • 7.6.6.2. Financial performance
      • 7.6.6.3. Product benchmarking
      • 7.6.6.4. Strategic initiatives
    • 7.6.7. Molnlycke Health Care AB
      • 7.6.7.1. Company overview
      • 7.6.7.2. Financial performance
      • 7.6.7.3. Product benchmarking
      • 7.6.7.4. Strategic initiatives
    • 7.6.8. Medtronic Plc
      • 7.6.8.1. Company overview
      • 7.6.8.2. Financial performance
      • 7.6.8.3. Product benchmarking
      • 7.6.8.4. Strategic initiatives